JP2024528127A5 - - Google Patents

Info

Publication number
JP2024528127A5
JP2024528127A5 JP2024505546A JP2024505546A JP2024528127A5 JP 2024528127 A5 JP2024528127 A5 JP 2024528127A5 JP 2024505546 A JP2024505546 A JP 2024505546A JP 2024505546 A JP2024505546 A JP 2024505546A JP 2024528127 A5 JP2024528127 A5 JP 2024528127A5
Authority
JP
Japan
Prior art keywords
pain
pharmaceutically acceptable
acceptable salt
pharmaceutical composition
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024505546A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024528127A (ja
JP7637827B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/071231 external-priority patent/WO2023006893A1/en
Publication of JP2024528127A publication Critical patent/JP2024528127A/ja
Publication of JP2024528127A5 publication Critical patent/JP2024528127A5/ja
Priority to JP2025023227A priority Critical patent/JP7836437B2/ja
Application granted granted Critical
Publication of JP7637827B2 publication Critical patent/JP7637827B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024505546A 2021-07-30 2022-07-28 疼痛、特に神経障害性疼痛、並びに/又は、at2r及び/若しくはat2r媒介性シグナル伝達に関連する他の疾患若しくは障害の治療のための化合物 Active JP7637827B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025023227A JP7836437B2 (ja) 2021-07-30 2025-02-17 疼痛、特に神経障害性疼痛、並びに/又は、at2r及び/若しくはat2r媒介性シグナル伝達に関連する他の疾患若しくは障害の治療のための化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163227555P 2021-07-30 2021-07-30
US202163227552P 2021-07-30 2021-07-30
US63/227,552 2021-07-30
US63/227,555 2021-07-30
PCT/EP2022/071231 WO2023006893A1 (en) 2021-07-30 2022-07-28 Compounds for the treatment of pain, in particular neuropathic pain, and/or other diseases or disorders that are associated with at2r and/or at2r mediated signaling

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025023227A Division JP7836437B2 (ja) 2021-07-30 2025-02-17 疼痛、特に神経障害性疼痛、並びに/又は、at2r及び/若しくはat2r媒介性シグナル伝達に関連する他の疾患若しくは障害の治療のための化合物

Publications (3)

Publication Number Publication Date
JP2024528127A JP2024528127A (ja) 2024-07-26
JP2024528127A5 true JP2024528127A5 (cg-RX-API-DMAC7.html) 2025-01-17
JP7637827B2 JP7637827B2 (ja) 2025-02-28

Family

ID=83149285

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024505546A Active JP7637827B2 (ja) 2021-07-30 2022-07-28 疼痛、特に神経障害性疼痛、並びに/又は、at2r及び/若しくはat2r媒介性シグナル伝達に関連する他の疾患若しくは障害の治療のための化合物
JP2025023227A Active JP7836437B2 (ja) 2021-07-30 2025-02-17 疼痛、特に神経障害性疼痛、並びに/又は、at2r及び/若しくはat2r媒介性シグナル伝達に関連する他の疾患若しくは障害の治療のための化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025023227A Active JP7836437B2 (ja) 2021-07-30 2025-02-17 疼痛、特に神経障害性疼痛、並びに/又は、at2r及び/若しくはat2r媒介性シグナル伝達に関連する他の疾患若しくは障害の治療のための化合物

Country Status (16)

Country Link
US (1) US20240368133A1 (cg-RX-API-DMAC7.html)
EP (1) EP4377307A1 (cg-RX-API-DMAC7.html)
JP (2) JP7637827B2 (cg-RX-API-DMAC7.html)
KR (1) KR20240063881A (cg-RX-API-DMAC7.html)
AU (2) AU2022318349B2 (cg-RX-API-DMAC7.html)
CA (1) CA3227194A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024000230A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024000880A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240041A (cg-RX-API-DMAC7.html)
DO (1) DOP2024000017A (cg-RX-API-DMAC7.html)
EC (1) ECSP24007288A (cg-RX-API-DMAC7.html)
IL (1) IL310330A (cg-RX-API-DMAC7.html)
JO (1) JOP20240019A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024001155A (cg-RX-API-DMAC7.html)
PE (1) PE20241304A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023006893A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022318349B2 (en) * 2021-07-30 2025-12-18 Confo Therapeutics N.V. Compounds for the treatment of pain, in particular neuropathic pain, and/or other diseases or disorders that are associated with at2r and/or at2r mediated signaling
KR20250011177A (ko) 2022-05-17 2025-01-21 일라이 릴리 앤드 캄파니 At2r 길항제 및 그의 용도
TW202440553A (zh) * 2023-03-29 2024-10-16 大陸商武漢人福創新藥物研發中心有限公司 作為at2r拮抗劑的雜環化合物
TW202502346A (zh) * 2023-06-16 2025-01-16 大陸商武漢人福創新藥物研發中心有限公司 作為at2r拮抗劑的雜環化合物及其用途
TW202515864A (zh) 2023-10-10 2025-04-16 大陸商武漢人福創新藥物研發中心有限公司 一種at2r拮抗劑及其用途
WO2025180473A1 (zh) * 2024-02-29 2025-09-04 上海汇伦医药股份有限公司 含四唑类化合物、其药物组合物及其用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU183178B (en) * 1979-07-13 1984-04-28 Thomae Gmbh Dr K Process for preparing new carboxylic acid derivatives
AU675660B2 (en) * 1992-07-17 1997-02-13 Merck & Co., Inc. Substituted biphenylmethylimidazopyridines
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
CA2180190A1 (en) * 1995-07-10 1997-01-11 Kazumi Ogata Benzylpiperazine derivatives
JPH09208570A (ja) * 1995-07-10 1997-08-12 Senju Pharmaceut Co Ltd ベンジルピペラジン誘導体
US6043358A (en) 1995-11-01 2000-03-28 Merck & Co., Inc. Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
US6124128A (en) 1996-08-16 2000-09-26 The Regents Of The University Of California Long wavelength engineered fluorescent proteins
ES2125206B1 (es) 1997-07-21 1999-11-16 Esteve Labor Dr Derivados de acil-piperazinil-pirimidinas, su preparacion y su aplicacion como medicamentos.
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
ES2325140T3 (es) 1998-04-20 2009-08-26 ABBOTT GMBH & CO. KG Amidas sustituidas con heterociclos como inhibidores de la calpaina.
ES2165274B1 (es) * 1999-06-04 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de indolilpiperidina como agentes antihistaminicos y antialergicos.
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
HK1078086A1 (en) 2003-04-09 2006-03-03 日本烟草产业株式会社 Heteroaromatic pentacyclic compound and medicinal use thereof
NZ555334A (en) 2004-12-24 2010-05-28 Spinifex Pharm Pty Ltd Method of treatment or prophylaxis of a neuropathic condition using AT2 receptor antagonist
CN102295636A (zh) 2005-07-29 2011-12-28 弗·哈夫曼-拉罗切有限公司 吲哚-3-基-羰基-哌啶和哌嗪衍生物
ES2583528T3 (es) 2010-09-07 2016-09-21 Astellas Pharma Inc. Compuesto de pirazoloquinolina
JP2012171868A (ja) * 2011-02-17 2012-09-10 Tsutomu Takeuchi N−ヘテロアリールピペラジン誘導体を有効成分とするbaffの結合阻害剤
WO2014159234A1 (en) 2013-03-14 2014-10-02 Merck Patent Gmbh Glycosidase inhibitors
NZ630908A (en) 2013-07-08 2017-08-25 Novartis Ag Heterocyclic compounds and methods of their use
SG10201900631TA (en) * 2014-08-01 2019-02-27 Nuevolution As Compounds active towards bromodomains
WO2016154075A1 (en) 2015-03-20 2016-09-29 Vertex Pharmaceuticals Incorporated Bicyclic heteroaryl compounds useful as inhibitors of the par-2 signaling pathway
JP7086395B2 (ja) 2016-03-04 2022-06-20 ヴァンダービルト ユニバーシティー 置換インドールMcl-1阻害剤
BR112018077075A2 (pt) * 2016-06-29 2019-04-30 Universite De Montreal heterociclos de biarilmetila
WO2018057588A1 (en) 2016-09-21 2018-03-29 Vertex Pharmaceuticals Incorporated Furo[3,2-b]pyridine compounds useful as inhibitors of the par-2 signaling pathway
JP7438962B2 (ja) 2018-03-23 2024-02-27 ベイジン タイド ファーマシューティカル カンパニー リミテッド 受容体阻害剤、同阻害剤を含む医薬組成物及びその使用
EP3886844A4 (en) 2018-11-28 2022-08-24 H. Lundbeck A/S Methods of treating disease with magl inhibitors
AU2022318349B2 (en) * 2021-07-30 2025-12-18 Confo Therapeutics N.V. Compounds for the treatment of pain, in particular neuropathic pain, and/or other diseases or disorders that are associated with at2r and/or at2r mediated signaling

Similar Documents

Publication Publication Date Title
JP2022191257A5 (cg-RX-API-DMAC7.html)
JP2024133474A5 (cg-RX-API-DMAC7.html)
JP2023524684A5 (cg-RX-API-DMAC7.html)
JP2021098728A5 (cg-RX-API-DMAC7.html)
JP2023541432A5 (cg-RX-API-DMAC7.html)
JP2022515293A5 (cg-RX-API-DMAC7.html)
JP2005502643A5 (cg-RX-API-DMAC7.html)
JP2009511450A5 (cg-RX-API-DMAC7.html)
JPWO2023195530A5 (cg-RX-API-DMAC7.html)
IL300151A (en) Combinations for cancer treatment
JP2022519744A5 (cg-RX-API-DMAC7.html)
JP2022551691A5 (cg-RX-API-DMAC7.html)
JP2021535147A5 (cg-RX-API-DMAC7.html)
JP2022554276A5 (cg-RX-API-DMAC7.html)
JP2020536048A5 (cg-RX-API-DMAC7.html)
JP2024516359A5 (cg-RX-API-DMAC7.html)
JP2022541938A5 (cg-RX-API-DMAC7.html)
JP2022500445A5 (cg-RX-API-DMAC7.html)
JP2019524888A5 (cg-RX-API-DMAC7.html)
JP2024543345A5 (cg-RX-API-DMAC7.html)
JP2014534229A5 (cg-RX-API-DMAC7.html)
JP2007530703A5 (cg-RX-API-DMAC7.html)
JP2024543111A5 (cg-RX-API-DMAC7.html)
CN109476611A (zh) 一种卤代化合物及其轴手性异构体
JP2005513036A5 (cg-RX-API-DMAC7.html)